JP4361279B2 - アファミンと組み合せたビタミンe製剤 - Google Patents
アファミンと組み合せたビタミンe製剤 Download PDFInfo
- Publication number
- JP4361279B2 JP4361279B2 JP2002584948A JP2002584948A JP4361279B2 JP 4361279 B2 JP4361279 B2 JP 4361279B2 JP 2002584948 A JP2002584948 A JP 2002584948A JP 2002584948 A JP2002584948 A JP 2002584948A JP 4361279 B2 JP4361279 B2 JP 4361279B2
- Authority
- JP
- Japan
- Prior art keywords
- afamin
- vitamin
- disease
- pharmaceutical composition
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
本発明によれば、この目的はアファミン含有製剤、特にビタミンEとの組み合わせによる製剤により達成され、これを用いて酸化ストレス治療用、特に神経変性性疾患の治療用製剤を製造することができる。本発明によれば、驚くべきことに、ビタミンEとアファミンを組み合わせることにより、改善された特性を有するビタミンE製剤、特に増大した抗酸化作用を有するビタミンE製剤を提供できることが見い出された。
α−トコフェロールは、細胞膜の酸化ラジカル障害を予防する可能性があり、このような製剤に関し、ハンチントン病の進行の遅延が議論されている。特に、抗酸化療法は、ハンチントン病の進行において、運動能力減少速度を遅延させる可能性がある(Peyser et al., Am. J. Psychiatry, 152 (1995), 1771-1775)。
更なる態様において、本発明は、急性神経変性性疾患、特にてんかん、外傷及び脳虚血(例えば卒中)の治療用製剤を製造するための、アファミンの使用、特にビタミンEとの組み合わせによる使用に関する。
本発明を以下の実施例及び図面によってより詳細に説明するが、これらは本発明を限定するものではない。
3−NP病変とハンチントン病(HD)との機構的及び病理的類似性より、3−NPは代替HDモデルとして提唱されている。マロネート及び3−NPはコハク酸デヒドロゲナーゼのインヒビターであり、HDにおいて観察されるものと類似のエネルギーの損失及び病変を生ずる。3−NPの全身投与は、HDのものに相当する進行性歩行悪化を引き起こす。3−NPは高度に選択的な線条体の変性を引き起こす。3−NPがミトコンドリアのクエン酸回路を不可逆的に阻害し、ATP値の減少及びラクテート濃度の増加をもたらすという点で、興奮毒性病変とは機構的に異なる。
脳球状体を抽出して1週間培養後、D、L−α−トコフェロール(0.1mM)を培地に添加した。2週齢の球状体を6ウェルプレートに播いた。曝露後すぐに培地を2mlの新鮮培地と交換した。球状体を、3−NP(0.5及び5mM、pH7〜8に調製)に、又は保護物質であるビタミンE(0.1mM)、グルタチオン(1mM)、DTT(0.25mM)、LNAME(N(G)−ニトロ−L−アラニン−メチルエステル)(0.1mM)、アファミン(ビタミンE(0.3及び3μg/ml)なし)若しくは3−NPと保護物質との組み合わせに5日間曝露した。2日後、新たに調製した3−NP及び保護物質を培地に添加した(Mathews et al., J. Neurosci, 18(1) (1998), 156-163); Borlongan et al., Neurosci Biohav. Res. 21(3) (1997), 289-293)。
アファミンの神経保護効果を、ニワトリ胚の単離皮質神経をアッセイすることにより調べた。低血清アッセイ及び2つの病変アッセイ、即ちP−アミロイド病変アッセイ及びH2O2病変アッセイにおいてアファミンの効果を試験した。
神経は、エタノールで処理した卵を破壊し、胚をプラスティックディッシュにおいて調製した。断頭切除後、脳半球を取り出して集めた。遊離組織及び髄膜を除去し、脳半球を機構的に解離させた。
各実験の最後に、培養物の生存率を、MTTアッセイにより、プレートリーダーを用いて570nmで試験した。
Claims (6)
- 神経変性性疾患を治療するための、アファミンを含む医薬組成物。
- さらにビタミンEを含む、請求項1に記載の医薬組成物。
- 神経変性性疾患が、アルツハイマー病、ハンチントン病、筋萎縮性側索硬化症、神経変性性痴呆、急性神経変性性疾患、パーキンソン病、及びダウン症候群に苦しむ患者において生じるアルツハイマー病と類似の変化から成る群より選択される、請求項1又は2に記載の医薬組成物。
- 急性神経変性性疾患が、てんかん、外傷、及び脳虚血からなる群より選択される、請求項3の医薬組成物。
- 酸化ストレスに関連する薬物の適用による副作用を治療するための、請求項1〜4のいずれか一項に記載の医薬組成物。
- 神経保護剤として使用される、請求項1〜5のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0069601A AT411014B (de) | 2001-04-30 | 2001-04-30 | Präparationen von vitamin e in kombination mit afamin |
PCT/AT2002/000132 WO2002087604A2 (de) | 2001-04-30 | 2002-04-30 | Präparationen von vitamin e in kombination mit afamin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004534749A JP2004534749A (ja) | 2004-11-18 |
JP4361279B2 true JP4361279B2 (ja) | 2009-11-11 |
Family
ID=3679284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002584948A Expired - Fee Related JP4361279B2 (ja) | 2001-04-30 | 2002-04-30 | アファミンと組み合せたビタミンe製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7365049B2 (ja) |
EP (1) | EP1385536B1 (ja) |
JP (1) | JP4361279B2 (ja) |
AT (2) | AT411014B (ja) |
CA (1) | CA2445048C (ja) |
DE (1) | DE50204475D1 (ja) |
ES (1) | ES2248601T3 (ja) |
WO (1) | WO2002087604A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT501348B1 (de) * | 2005-01-31 | 2008-10-15 | Vitateq Biotechnology Gmbh | Verfahren zur tumordiagnose |
US7753064B2 (en) * | 2007-09-13 | 2010-07-13 | Bravo Sports Corporation | Canopy latch system |
AT507325A1 (de) * | 2008-10-01 | 2010-04-15 | Univ Innsbruck | Verwendung von afamin |
KR101025612B1 (ko) * | 2008-11-10 | 2011-03-30 | 한국해양연구원 | 신규 화합물인 Ramalin 및 그 용도 |
US20140127703A1 (en) | 2011-06-28 | 2014-05-08 | Vitateq Biotechnology Gmbh | Method for Diagnosing Preeclampsia |
GB2511525A (en) * | 2013-03-05 | 2014-09-10 | Randox Teoranta | Methods and Compositions for the Diagnosis of Alzheimer's Disease |
EP3037824A1 (en) | 2014-12-22 | 2016-06-29 | Vitateq Biotechnology GmbH | Method for the detection and/or quantification of afamin |
CN109072179B (zh) * | 2016-02-18 | 2022-04-01 | 学校法人庆应义塾 | 细胞培养基、培养方法以及类器官 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652352A (en) | 1994-03-31 | 1997-07-29 | Amgen Inc. | Afamin: a human serum albumin-like gene |
AT407675B (de) * | 1999-06-25 | 2001-05-25 | Vita Tech Illmensee Dieplinger | Verfahren zur fertilitätsbestimmung von säugetieren, insbesondere von menschen |
-
2001
- 2001-04-30 AT AT0069601A patent/AT411014B/de not_active IP Right Cessation
-
2002
- 2002-04-30 US US10/476,236 patent/US7365049B2/en not_active Expired - Fee Related
- 2002-04-30 JP JP2002584948A patent/JP4361279B2/ja not_active Expired - Fee Related
- 2002-04-30 DE DE50204475T patent/DE50204475D1/de not_active Expired - Lifetime
- 2002-04-30 WO PCT/AT2002/000132 patent/WO2002087604A2/de active IP Right Grant
- 2002-04-30 EP EP02766574A patent/EP1385536B1/de not_active Expired - Lifetime
- 2002-04-30 CA CA2445048A patent/CA2445048C/en not_active Expired - Fee Related
- 2002-04-30 ES ES02766574T patent/ES2248601T3/es not_active Expired - Lifetime
- 2002-04-30 AT AT02766574T patent/ATE305796T1/de active
Also Published As
Publication number | Publication date |
---|---|
WO2002087604A3 (de) | 2002-12-19 |
ATE305796T1 (de) | 2005-10-15 |
EP1385536A2 (de) | 2004-02-04 |
DE50204475D1 (de) | 2006-02-16 |
CA2445048A1 (en) | 2002-11-07 |
ES2248601T3 (es) | 2006-03-16 |
WO2002087604A2 (de) | 2002-11-07 |
US7365049B2 (en) | 2008-04-29 |
JP2004534749A (ja) | 2004-11-18 |
US20040235718A1 (en) | 2004-11-25 |
WO2002087604A8 (de) | 2005-03-10 |
AT411014B (de) | 2003-09-25 |
EP1385536B1 (de) | 2005-10-05 |
ATA6962001A (de) | 2003-02-15 |
CA2445048C (en) | 2011-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arcangeli | Pycnogenol® in chronic venous insufficiency | |
US10016450B2 (en) | Anti-glycation methods and compositions | |
AU2005268402B2 (en) | Composition containing statins and omega-3 fatty acids | |
JP2009506057A (ja) | 脂肪細胞の脂肪蓄積を管理する方法 | |
EP0724877A1 (fr) | Association de fénofibrate et de vitamine E, utilisation en thérapeutique | |
JP6157572B2 (ja) | 神経変性または神経・筋変性疾患の治療方法およびその治療薬 | |
CA2713104A1 (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
US20020192314A1 (en) | Dietary supplement compositions | |
JP4361279B2 (ja) | アファミンと組み合せたビタミンe製剤 | |
WO2004075883A1 (en) | Use of curcumin derivatives or cape in the manufacture of a medicament for the treatment of neuroprotective disorders | |
MXPA04009412A (es) | Metodos neuroprotectores, composiciones y metodos para seleccion de los mismos. | |
JP4520089B2 (ja) | ルブロフサリン配糖体含有組成物 | |
JP3977889B2 (ja) | 蕎麦殻抽出物を有効成分とする薬剤 | |
KR101840092B1 (ko) | 에틸 파이루베이트(ethyl pyruvate)를 포함하는 말초신경계 퇴행성 질환의 예방 또는 치료용 약학적 조성물 | |
Khatija et al. | Biochemical study on the anti-hyperglycemic effects of coconut testa (Cocos nucifera L.) and red kidney bean (Phaseolus vulgaris) seed coat in Streptozotocin-induced diabetic rats | |
CA2664982C (en) | Cleavable carnitine compound | |
AU2002338484B2 (en) | Preparations containing a combination of vitamin E and afamin | |
JPH06199694A (ja) | 血圧安定化治療剤 | |
JP2002233332A (ja) | 高い抗酸化活性を有するイチョウ葉エキス含有組成物 | |
US8128969B2 (en) | Hypoglycemic composition containing acacia bark derivative | |
KR100594378B1 (ko) | Sal-2를 유효성분으로 함유하는 항산화, 항염증 또는항노화용 조성물 | |
KR20050089238A (ko) | 황련의 알콜 추출물 또는 그로부터 분리된 베르베린을유효성분으로 하는 당뇨합병증의 예방 및 치료용 조성물 | |
KR20100137674A (ko) | 리나룰을 유효성분으로 함유하는 콜레스테롤 저하용 조성물 | |
JP2011052028A (ja) | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081017 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090721 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090812 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120821 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130821 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |